Creon Oral Capsule, Gastro-Resistant Pellets 12000-60000-38000U Drug Medication Dosage Information
show timeout overlay link

Your Session Is About to Expire

This online session is about to expire due to inactivity. Click Continue to return to page.

  • Weekly Ad

Creon: Oral capsule, gastro-resistant pellets (12000-60000-38000U)

Also see:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics

Visit Drug Summary Page
Drug Image file DrugItem_16255.JPG
Creon 12,000unit DR Cap
AbbVie US LLC formerly Solvay Pharmaceuticals Inc an Abbott Company
Pill Identification: CREON 1212 
Drug Image file DrugItem_16255.JPG
Creon 12,000unit DR Cap
AbbVie US LLC formerly Solvay Pharmaceuticals Inc an Abbott Company
Pill Identification: CREON 1212 

CVS Pharmacy Patient Statistics for Creon: Oral capsule, gastro-resistant pellets(12000-60000-38000U)
Generic vs. Brand Name Usage*
*Brand contains same active ingredient but may not represent FDA-approved generic equivalent
Usage By Strength
In-Depth Information

Creon (Lipase 12,000unit) Minimicrospheres Delayed-Release Capsule

NDC: 000321212
  • Prescription Required
  • Not a Controlled Drug
    (CSA Schedule)
  • FDA Approved




FDA approved for the following conditions:
Pancreatectomy, Cystic Fibrosis, Pancreatic Insufficiency

Storage Information
Store at room temperature (up to 77 degrees F)
Protect from moisture
Creon (Lipase 12,000unit) Minimicrospheres Delayed-Release Capsule
Drug Image file DrugItem_13774.JPG
AbbVie US LLC formerly Solvay Pharmaceuticals Inc an Abbott Company
Pill Identification: CREON 1212 
Shape: capsule
Color: brown
Drug Image file DrugItem_16255.JPG
AbbVie US LLC formerly Solvay Pharmaceuticals Inc an Abbott Company
Pill Identification: CREON 1212 
Shape: capsule
Color: brown

Reported Side Effects for Creon (Lipase 12,000unit) Minimicrospheres Delayed-Release Capsule

Skin Rash Incidence:
<1.0%*
Severity: MILD
Onset: EARLY
Rash With Pustules Incidence:
<1.0%*
Severity: MILD
Onset: EARLY
Breathing Difficulties Incidence:
<1.0%*
Severity: SEVERE
Onset: RAPID
Anaphylactoid Reactions Incidence:
<1.0%*
Severity: SEVERE
Onset: RAPID
Hives Incidence:
<1.0%*
Severity: MILD
Onset: RAPID
Itching Incidence:
<1.0%*
Severity: MILD
Onset: RAPID
Low Blood Sugar Incidence:
2.0%*
Severity: MODERATE
Onset: EARLY
Increased Blood Sugar Incidence:
2.0%*
Severity: MODERATE
Onset: DELAYED
Infection Incidence:
3.0-11.0%*
Severity: MILD
Onset: DELAYED
Stomach Pain Incidence:
3.0-18.0%*
Severity: MILD
Onset: EARLY
Headache Incidence:
3.0-15.0%*
Severity: MILD
Onset: EARLY
Gas Incidence:
3.0-9.0%*
Severity: MILD
Onset: EARLY
Lightheadedness Incidence:
4.0-6.0%*
Severity: MILD
Onset: EARLY
Sore Throat Incidence:
4.0%*
Severity: MILD
Onset: DELAYED
Cough Incidence:
4.0-10.0%*
Severity: MILD
Onset: DELAYED
Vomiting Incidence:
6.0%*
Severity: MILD
Onset: EARLY
Nose Bleed Incidence:
7.0%*
Severity: MILD
Onset: DELAYED
Upset Stomach Incidence:
10.0%*
Severity: MILD
Onset: EARLY
Loose Stools Incidence:
10.0%*
Severity: MILD
Onset: EARLY
Enlarged Lymph Nodes Incidence:
11.0%*
Severity: MODERATE
Onset: DELAYED
Ear Pain Incidence:
11.0%*
Severity: MILD
Onset: EARLY
Stuffy Nose Incidence:
14.0%*
Severity: MILD
Onset: EARLY
*This is an approximate aggregated range of reported side effects from clinical studies performed on this drug. Your experience with this drug may be different.
Pregnancy & Lactation Information
FIRST Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

SECOND Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

THIRD Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

Lactation

Caution - Not enough information is available to rule out harm to infants when this drug is taken by nursing mothers.


Learning More About
Visit the Drug Summary page where you can:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics
Learn More
Patient Experiences with Creon

We want to help you stay educated about the medications you are taking. View other
patient's observations and share your own.

Be sure to consult your health care provider before taking any medications. Other
patient's comments should not be considered medical advice or health care provider
recommendations.